BACKGROUND: Extranodal (or extracapsular) extension (ENE) is an adverse prognostic factor in patients with head and neck cancers who undergo primary surgery. However, the significance of ENE in human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) is not well established, and single-institution studies have not established that ENE predicts inferior outcome. The authors investigated the prognostic value of ENE in HPV-positive patients who underwent primary surgery and whether adjuvant chemoradiation improved overall survival (OS) compared with radiation alone in ENE-positive patients. METHODS: Patients who underwent primary surgery for pathologic T1 (pT1) through pT4 tumors, pathologic N1 (pN1) through pN3 lymph node status, HPVpositive OPSCC were identified in the National Cancer Data Base from 2010 through 2012. Features associated with ENE were analyzed. Univariable and multivariable Cox regression analyses identified predictors of OS. The effect of adjuvant treatment on OS in ENE-positive cohort was also evaluated. RESULTS: In total, 1043 patients met inclusion criteria, among whom 43.5% were ENEpositive. Of the ENE-positive patients who had treatment details available, 72% received concurrent chemoradiotherapy, 16% received radiotherapy, and 12% received no adjuvant treatment. After a median follow-up of 28.4 months, ENE was associated with worse 3-year OS (89.3% vs 93.6%; P 5 .01). On multivariable analysis that included involved lymph nodes, only ENE, lymphovascular invasion, pT3/pT4 tumors, and Charlson-Deyo score were associated with worse OS. Among ENE-positive patients, there was no difference in 3-year OS between those who received adjuvant concurrent chemoradiotherapy versus radiotherapy alone (89.6% vs 89.3%, respectively; P 5 .55). Propensity score-matched comparison revealed similar results. CONCLUSIONS: ENE is associated with inferior OS in patients with HPV-positive OPSCC. However, OS was not better with adjuvant chemoradiotherapy compared with radiotherapy alone in ENE-positive patients. The current findings support the need for prospective studies of adjuvant chemoradiation in HPV-positive patients with ENE.
INTRODUCTION
Extranodal extension (ENE) is an adverse prognostic factor for patients with head and neck cancer who undergo primary surgery and has been associated with inferior locoregional recurrence and survival. [1] [2] [3] Seminal trials that began in the late 1990s demonstrated that adjuvant concurrent chemoradiotherapy (CRT) improved locoregional control and diseasespecific survival (DSS) in patients who had head and neck cancer with specific high-risk features. [4] [5] [6] A subsequent Bernier combined analysis concluded that the benefit of adjuvant CRT over adjuvant radiotherapy alone (RT) was most specific to patients who had involved surgical margins and/or ENE, and these 2 risk factors are now the standard indications for postoperative CRT. 7, 8 Nevertheless, although CRT led to an approximately 13% 5-year survival benefit in European Organization for Research and Treatment of Cancer Trial 22931, it was also associated with a substantial increase in grade 3 mucosal toxicity from, 21% to 41% (P 5 .001).
However, there has been limited investigation of the prognostic value of ENE specifically in human papillomavirus (HPV)-associated head and neck cancers. HPVassociated oropharyngeal cancer is characterized by better outcomes after primary surgery or definitive CRT compared with HPV-negative disease. [9] [10] [11] [12] The percentage of oropharyngeal squamous cell carcinoma (OPSCC) associated with HPV has increased substantially over the past 20 years, and such cancers were likely a small proportion of those enrolled in the trials by Bernier et al and Cooper et al. [13] [14] [15] [16] Because patients with HPV-positive OPSCC tend to be younger, have less tobacco exposure and fewer medical comorbidities, and experience better outcomes, treatment de-escalation is the subject of active clinical investigation in favorable-risk, HPV-positive cancers. 17 Single-institution, retrospective studies of HPVpositive OPSCC treated with up-front surgery have not demonstrated inferior outcomes in ENE-positive patients. [18] [19] [20] This has led to considerable interest in questioning whether adjuvant CRT is beneficial in patients who have HPV-positive OPSCC with ENE. Here, we analyzed data from the National Cancer Data Base (NCDB) to evaluate the prognostic value of ENE in HPV-positive OPSCC. In addition, we examine whether adjuvant CRT in patients with OPSCC who have ENE is associated with improved clinical outcomes compared with adjuvant RT alone.
MATERIALS AND METHODS

Study Design and Data Source
The NCDB is a joint program of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The data includes 70% of newly diagnosed cancers in the United States, including case records from over 1500 Commission on Canceraccredited hospitals. The study was exempt from the Yale University Institutional Review Board.
We identified 1043 patients aged 18 years who had pathologic T1 (pT1) through pT4 tumors, pathologic N1 (pN1) through pN3 lymph node status, M0 OPSCC diagnosed during 2010 through 2012 who underwent primary surgery with negative surgical margins. We included only those who had pathologic confirmation of tumor association with high-risk HPV, as coded by NCDB guidelines (HPV status was not recorded before 2010). Specifically, the NCDB coding instructions for HPV status require recording results from any HPV tests performed on pathologic specimens from a primary tumor or metastatic site, including the lymph nodes.
HPV status was determined by direct HPV testing and, in a subset, viral strains were also documented as high risk or low risk; only high-risk HPV strains were considered HPV-associated in this study. Additional exclusion criteria were metastatic disease, palliative-intent treatment, neoadjuvant chemotherapy or preoperative radiotherapy, and missing information regarding ENE status, surgical margin status, or clinical follow-up. The inclusion and exclusion criteria are summarized in Figure 1 . Oropharyngeal primaries were defined according to International Classification of Diseases for Oncology, third edition, site codes C01.9 (base of tongue), C05.1 through C05.2 (soft palate and uvula), C09.0 through C09.9 (tonsil), and C10.0 through C10.9 (vallecula, anterior epiglottis surface, oropharyngeal wall, and oropharynx not otherwise specified). Oral cavity subsites, larynx, and hypopharynx primary sites were excluded. Squamous cell carcinoma International Classification of Diseases for Oncology, third edition, histology codes 8052, 8070 through 8079, 8083, and 8084 were used. Nonsquamous cell histologies (spindle cell carcinoma, adenocarcinoma, lymphoepithelial carcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, and mucinous carcinomas) were excluded. ENE was defined according to NCDB coding guidelines and was based assessment of ENE in resected regional lymph nodes as documented by histo-pathology reports. In a subset of tumors, ENE could be further characterized as macroscopic or microscopic according to the pathology Figure 1 . Study inclusion and exclusion criteria are illustrated. CRT indicates chemoradiotherapy; ENE2, extranodal extension-negative; ENE1, extranodal extension-positive; HPV, human papillomavirus; M0, negative for metastasis; pN1-3, pathologic lymph node status 1 through 3; pT1-4, pathologic tumor classification pT1-pT4; RT, radiotherapy; SCC, squamous cell carcinoma.
report. The definition of concurrent CRT required patients to receive chemotherapy within 30 days before or after the start of RT.
Demographic features were dichotomized when appropriate and were included in univariable and multivariable analyses. These features included age at diagnosis (55 or >55 years), sex, race (white or nonwhite), annual income (<$35K or $35K), treatment facility (academic or nonacademic), patient travel distance (<20 or 20 miles), facility volume (higher or lower), insurance (private or nonprivate), and Charlson-Deyo comorbidity index (CD) (0 or 1). The dichotomization of several variables, including age, was based on median values to ensure relatively equal distribution. A high-volume facility was defined as 1 with an annual case volume in the 90th percentile or higher. 21 Other clinical features analyzed included tumor grade (1-2 or 3), lymphovascular invasion (LVI), number of involved lymph nodes (1-4 or 5), size of the largest lymph node (3 or >3 cm), pathologic tumor classification (pT1-pT2 or pT3-pT4), and pathologic lymph node status (pN1, pN2, or pN3).
Statistical Analysis
Two-sided statistical tests were used, and P values < .05 were considered statistically significant. Patient demographics and clinicopathologic features were compared between ENE-positive and ENE-negative patients using chi-square tests. Overall survival (OS) was compared between ENE-positive and ENE-negative patients using the Kaplan-Meier method and log-rank tests. The clinicopathological features that approached significance (P < .1) on univariable analysis plus other key clinical features were included in multivariable Cox regression to identify factors that were significantly associated with OS. The adjuvant therapy type (CRT or RT) was excluded from multivariable regression, because the variable exhibited significant collinearity with ENE positivity, in that patients with ENE were much more likely to receive CRT. We then performed a subset analysis of OS by ENE positivity only among patients who had 1 positive lymph node to minimize the confounding influence of metastatic lymph nodes on ENE status.
Among ENE-positive patients, we identified patient demographics and clinical factors that were significantly associated with treatment allocation using the chi-square test. A multivariable logistic regression model was constructed using variables that were considered clinically important or that approached statistical significance on univariable logistic regression (P < .1). The effect of adjuvant treatment on OS in the ENE-positive cohort was then analyzed using the log-rank test. To account for other clinical features that differed between the adjuvant CRT and RT groups, propensity score matching of variables that were significant on univariable logistic regression was performed using bootstrapping with 1-to-1 nearestneighbor matching without replacement and a caliper distance of 25% of the standard deviation of the pooled propensity scores. All statistical analyses were performed using Stata SE version 13.1 (StataCorp, College Station, Tex).
RESULTS
Impact of ENE Status
We identified 1043 patients with pT1 through pT4, pN1 through pN3, M0, HPV-positive OPSCC who underwent primary surgery with negative surgical margins and had ENE status recorded. Of these, 454 patients (43.5%) were positive for ENE, and 589 (56.5%) were negative. The median follow-up was 28.4 months (interquartile range, 20.5-37.1 months). The presence of ENE was associated with other high-risk clinicopathologic features, including as pathologic tumor classification pT2 and LVI (all P < .05) ( Table 1 ). The presence of ENE, compared with its absence, had a significant association with greater numbers of pathologically involved lymph nodes (mean, 2.2 vs 3.9 involved lymph nodes; P < .001) and with the pathologic size of the largest lymph node (median size, 3.6 vs 3.1 cm; P < .001). ENE was more likely to be present at academic and high-volume treatment facilities. In addition, adjuvant CRT was more likely to be received by patients with ENE-positive than b those with ENE-negative disease (82.2% vs 44.6%, respectively; P < .001).
Patients who had ENE had inferior OS compared with ENE-negative patients, with a 3-year OS rate of 89.3% versus 93.6%, respectively (log-rank P 5 .010) (Fig. 2) . The factors associated with worse OS on univariable Cox regression included ENE, LVI, 5 involved lymph nodes, CD comorbidity scores 1, and lack of private insurance (all P < .05) ( Table 2 ). It is noteworthy that there was no detectable difference in OS between patients with macroscopic or microscopic ENE (Supporting Fig. 1 ; see online supporting information). On multivariable Cox regression, only ENE, LVI, pT3/pT4 tumors, and CD scores 1 were significantly associated with worse OS (all P < .05); we also observed that the presence of 5 involved lymph nodes was not associated with worse OS on multivariable analysis (hazard ratio [HR], 0.87; 95% confidence interval [CI], 0.48-1.56).
To isolate the association of ENE with OS and to reduce potential confounding from the number of metastatic cervical lymph nodes, we examined OS stratified by ENE in only patients who had 1 metastatic lymph node (Fig. 3) . Even in this subset, the 3-year OS of patients with ENE was worse than that of those without ENE (90.8% vs 96%; P 5 .033). 
Adjuvant Therapy in ENE-Positive Patients
We subsequently limited our analysis to ENE-positive patients wo had adjuvant treatment specified to examine whether the type of adjuvant therapy was associated with differences in OS. Among the 371 ENE-positive patients who received adjuvant treatment, 305 (82.2%) received adjuvant concurrent CRT, and the remaining 66 (17.8%) received RT. On univariable logistic regression, the only factors that had a significant association with a higher likelihood of receiving CRT were 5 involved lymph nodes, pN2 or pN3 lymph node status, and male sex (Table 3) . Age 55 years (P 5 .34) and CD scores 1 (P 5 .98) were not significantly associated with receipt of CRT. On multivariable logistic regression, pN2 through pN3 lymph node status was the only factor associated with a significantly higher likelihood of receiving concurrent CRT (odds ratio, 2.61 [P 5 .016] for pN2; odds ratio, 6.39 [P 5 .024] for pN3) ( Table 4) . Eleven of 66 patients were recommended adjuvant chemotherapy but refused, and 1 patient reportedly was not recommended chemotherapy because of medical comorbidities. The rationale for omitting chemotherapy was not documented for the remaining patients. When evaluating the effect of adjuvant treatment on OS only in ENE-positive patients, we observed no significant difference in OS between adjuvant CRT or RT (log-rank test; P 5 .55) (Fig. 4a) . The 3-year OS rate for those who received adjuvant CRT was 89.3% (95% CI, 84.1%-92.9%) compared with 89.6% (95% CI, 75.4%-95.8%) for those who received RT. Propensity score matching produced an even distribution of 132 patients between the adjuvant CRT and RT groups. In this matched comparison, there remained no significant difference in OS between adjuvant CRT and adjuvant RT (3-year OS, 89.3% vs 89.6%; P 5 .44) (Fig. 4b) .
DISCUSSION
In the current study, 1043 patients with HPV-associated OPSCC who had negative margins after primary surgery were analyzed to determine the effect of ENE positivity on OS. The observed ENE rate of 43.5% was slightly lower than rates reported by single-institution reports of HPV-positive OPSCC: 59.2% from the University of Pittsburgh and 52% from Washington University, although might be explained in part by patient selection at those high-volume surgical centers. 18, 19 Also, in contrast to those reports, we observed a significant association between ENE positivity and with inferior OS; and LVI and higher comorbidity scores were also associated with worse OS on multivariable analysis. It is noteworthy that higher pathologic grade was not independently associated with OS on univariable or multivariable analyses. This is an important finding, because smaller singleinstitution reports have failed to detect a significant association between ENE and clinical outcomes in HPVpositive patients. In the Washington University study of 152 patients with HPV-associated OPSCC who underwent minimally invasive surgery, a 3-year DFS rate of 89% (95% CI, 84%-95%) was observed in ENEpositive patients versus 94% (95% CI, 83%-100%) in ENE-negative patients (P 5 .21); this modest difference was not statistically significant in this smaller cohort. 19 Similarly, a University of Pittsburgh study of 76 patients with HPV-associated OPSCC reported that the 2-year DSS was not significantly different among patients with or without ENE (P 5 .94). 18 In an update from that group, ENE-positive patients reportedly had a 5-year DSS rate of 85% (95% CI, 64%-94%) compared with 89% (95% CI, 74%-98%) in those without ENE. 22 One explanation for our finding of a statistically significant difference in survival between patients with ENEpositive and ENE-negative, HPV-positive disease, despite the conclusions of smaller single-institutions studies, is the greater power associated with the much larger numbers of patients in the current study. A noteworthy difference among the 3 studies is the outcome measured (OS vs DFS vs DSS); however, because the majority of patients with recurrent cancer ultimately die of disease given the limited curative salvage options, differences in DFS and DSS are likely to translate into differences in OS.
The seemingly modest 4% difference in 3-year OS among patients with and without ENE reported here should be interpreted in the context of our finding that ENE was associated with an HR of 1.89 (P 5 .046) on multivariable analysis. This suggests that ENE is independently associated with nearly 2 times higher hazard of death. Only pT classification (pT3-pT4: HR, 2.62; P 5 .007) and higher medical comorbidity scores (CD score, 1-2; HR, 2.15; P 5 .013) were associated with a higher HR than ENE on multivariable analysis. These findings clearly indicate that ENE appears to be an important adverse factor after primary surgery in patients with HPVassociated OPSCC. Moreover, the OS decrease attributed to ENE also must be considered in context of the collective cohort OS. The 3-year OS rate of 91.8% in all patients (and 93.6% in ENE-negative patients) in the current study suggests both an excellent baseline prognosis and reveals how a 4% survival detriment can substantially augment the risk of death relative to baseline.
Another intriguing finding of this study was the superb oncologic outcomes observed in patients who had HPV-positive OPSCC after primary surgery. Admittedly, when evaluating such good observed outcomes, it is important to note that: 1) this study only included patients who had negative surgical margins, and 2) these were highly selected patients who were deemed appropriate surgical candidates. Indeed, retrospective studies have demonstrated excellent survival using either primary CRT or primary surgical approaches for HPV-positive oropharyngeal cancers, 23 and the choice of treatment can be determined by patient and physician preferences, logistics, and toxicity concerns as opposed to concerns about differences in survival.
The association of 5 metastatic lymph nodes with worse outcomes in patients with HPV-associated disease was observed notably by Sinha et al and is now incorporated into pathologic lymph node staging by the eighth edition of the American Joint Committee on Cancer staging guideline for p16-positive OPSCC. 24 In fact, this research from the Washington University group suggests that the number of metastatic lymph nodes (but not ENE) is an important risk factor for recurrence in resected, HPVpositive OPSCC. In contrast, we observed that the presence of 5 metastatic lymph nodes was not significantly associated with OS in multivariable analyses. This does not necessarily suggest that the number of pathologically involved lymph nodes is not an important adverse prognostic factor. In fact, the HR associated with 5 metastatic lymph nodes (HR, 1.81; P 5 .086) was similar to that of ENE (HR, 1.89; P 5 .046). Instead, our findings suggest that both ENE and the number of metastatic lymph nodes should continue to be evaluated as potentially important, negative prognostic factors in patients with HPV-associated OPSCC who undergo primary surgery, especially because more involved lymph nodes are associated with a higher likelihood of ENE. Therefore, to minimize the confounding influence of the number of metastatic lymph nodes on the OS decrease attributed to ENE, we performed both multivariable and subset analyses. ENE was still a significant predictor of worse OS in both: 1) multivariable analysis, which included consideration of metastatic lymph nodes; and 2) a subgroup of patients with a single metastatic lymph node, suggesting that the significance of ENE is independent of the number of involved lymph nodes.
Nevertheless, just because ENE may be associated with worse outcomes in this study does not necessarily suggest that adjuvant treatment intensification with CRT is invariably beneficial. In patients with ENE, we observed that the 3-year OS rate was similar for the 305 patients who received CRT compared with the 66 who received RT (89.6% vs 89.3%, respectively; log-rank test, P 5 .552), and a propensity score-matched analysis produced similar results. These results are consistent with a previously published Washington University study of 113 patients who had ENE noted on their pathology reports. In that group, the 3-year DFS rate was 91.8% among 65 patients who received RT versus 94.5% among 48 patients who received chemoRT (P 5 .74). 19 Indeed, because we were unable to detect a benefit with adjuvant CRT over adjuvant RT alone in the ENE-positive cohort, these findings provide further support that clinical trials are needed to elucidate which subgroups of patients with HPV-positive OPSCC after surgery may benefit from adjuvant treatment intensification.
Although our findings may appear to be discordant with conclusions of the Bernier combined analysis, several issues may limit a direct extrapolation of the results of that analysis to an HPV-positive population. First, oropharyngeal primaries made up only 42% of patients in Radiation Therapy Oncology Group study 9501 and 30% of patients in European Organization for Research and Treatment of Cancer (EORTC) 22931. In addition, those studies also took place before routine HPV testing and may have had a lower proportion of HPV-positive patients than would be expected with a more modern cohort given the rise of HPV-positive OPSCC in the last 2 or 3 decades. 13 Because patients with HPV-positive oropharyngeal cancer likely comprised a minority of patients in those trials, HPV-positive patients who have ENE or positive margins may not necessarily benefit from adjuvant CRT. Finally, some have begun to note the possibility of interobserver variability when assessing ENE. For instance, a Washington University study applied pathologic re-examination of ENE status and observed that, whereas ENE was present in 82% on initial clinical report, re-review determined ENE positivity in only 52% of patients, suggesting the importance of standardizing definitions of ECE. 19 Several ongoing clinical trials are investigating treatment de-intensification in HPV-positive patients who undergo surgery. For instance, the high-risk arm of the PATHOS trial (clinicaltrials.gov identifier NCT02215265) randomizes patients with ENE or microscopically close/positive margins (<1 mm) to receive either adjuvant CRT or RT. 25 Until results from those trials are available, concurrent cisplatin-based CRT remains the standard of care for patients with ENE-positive OPSCC regardless of HPV status. Nonetheless, it may be more challenging to demonstrate a benefit of adjuvant treatment intensification in patients who have HPVassociated OPSCC with ENE given the smaller survival detriment associated with ENE in those who have HPVpositive disease compared with HPV-negative disease. For example, the University of Pittsburgh group observed that ENE was associated with a 28% DSS decrement in patients with oral cavity malignancies (3-year absolute DSS, 43% vs 71%, respectively), 18, 19 which is substantially higher than the 4% absolute OS difference observed in the current study. Future studies of adjuvant treatment for HPV-associated OPSCC may need to be designed with more power than studies of HPV-negative or head and neck cancers outside the oropharynx.
The major limitations of this study primarily stem from the inherent inability of retrospective studies to fully control for treatment selection biases because of unmeasured confounding variables. We used multivariable analysis and propensity score matching to adjust for the effects of recorded variables, although we recognize there are likely unrecorded variables that may still confound our findings, such as performance status, smoking history, or extent of ENE. We also cannot comment on the utility of concurrent chemotherapy on endpoints other than OS, such as locoregional control, DFS, DSS, and treatmentrelated toxicities, because these data are not collected by the NCDB. Furthermore, the lack of an observed difference in OS between patients with microscopic or
